

Therapeutics for Women's Health: Technologies and Global Markets

<https://marketpublishers.com/r/T60FB243499EN.html>

Date: January 2022

Pages: 258

Price: US\$ 2,750.00 (Single User License)

ID: T60FB243499EN

Abstracts

Report Scope:

This report is an analytical business tool that comprehensively evaluates the global market for women's health therapeutics. The format of the study is organized around the following topics -

Detailed study around women's diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.

Disease incidence and prevalence.

Regulatory structure of pharmaceutical industry.

Market characterization, unmet need, market size and segmentation.

Market drivers and restraints.

Detailed market projections through 2026.

Competition and market shares.

Pricing and reimbursement.

Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.

Observations and conclusions regarding the future of market for women's health therapeutics.

Profiles of market participants and associations.

Report Includes:

58 data tables and 56 additional tables

An overview of the global market and technologies for women's health therapeutics

Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026

Detailed study around women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden

Discussion on aging and women's health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer

Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials

Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast

Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies

Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
What's New in this Update?
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 OVERVIEW OF TECHNOLOGIES AND GLOBAL MARKETS

Disease Overview and Definitions
Historical Background
Market Driving Factors and Opportunities
Aging Female Population
Government Involvement and Increased Funding
Increasing Awareness Regarding Women's Disorders and Treatments
Market Restraints
Poor Diagnosis
Availability of Alternate Treatment Options and Lifestyle Changes
Unavailability of Novel Treatments
High Treatment Cost of Osteoporosis
Opportunities
Rising Female Population in Asia-Pacific
Increased Demand for Technology Innovation
Mergers and Acquisitions

CHAPTER 4 IMPACT OF COVID-19 PANDEMIC

Implications on Women's Health and Diagnosis
Implications on Cancer Treatment

Impact on Oncology Pharmaceuticals Market

CHAPTER 5 PIPELINE ASSESSMENT AND ANALYSIS

Women's Health Therapeutics: Key Clinical Trial Developments

List of Drugs in Pipeline

Overview of Osteoporosis Drug Development Pipeline

Late-stage Pipeline Drugs

CHAPTER 6 REGULATORY STRUCTURE

Overview of Regulations

U.S.

Canada

Europe

Japan

CHAPTER 7 MARKET BREAKDOWN BY WOMEN'S HEALTH DISORDER

Introduction

Menopause-Related Diseases

Overview

Symptoms

Risk Factors

Epidemiology and Economic Burden

Diagnosis

Treatments

Market Size and Forecast

Postmenopausal Osteoporosis

Overview

Epidemiology and Economic Burden

Diagnosis

Treatments

Market Size and Forecasts

Endometriosis

Overview

Epidemiology and Economic Burden

Diagnosis

Treatments

Market Size and Forecasts
Polycystic Ovary Syndrome
Overview
Etiology
Reducing PCOS Risk
Epidemiology and Economic Burden
Disease Symptoms and Risk Factors
Diagnosis
Treatments
Market Size and Forecasts
Breast Cancer
Overview
Market Size and Forecasts

CHAPTER 8 MARKET BREAKDOWN BY REGION

Introduction
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
Rest of the World
South America
Middle East and Africa

CHAPTER 9 PRICING AND REIMBURSEMENT

Overview of Pricing and Reimbursement

U.S.

Canada

Europe

Japan

CHAPTER 10 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS

Market Players and Strategies

Blockbuster Breast Cancer Pharmaceutical Brands

Patent Analysis

List of Key Patents

Key Developments

Mergers and Acquisitions

Development of Innovative Products/Novel Product Launch

Agreements, Collaborations and Partnerships

Key Products

CHAPTER 11 COMPANY PROFILES

ABBVIE INC.

AMGEN INC.

ASAHI KASEI

ASTRAZENECA PLC

BAYER AG

BRISTOL-MYERS SQUIBB

DAIICHI SANKYO CO. LTD.

ELI LILLY AND CO.

EISAI

F. HOFFMANN-LA ROCHE LTD.

GILEAD SCIENCES INC.

JOHNSON & JOHNSON SERVICES INC.

MERCK & CO. INC.

MERCK KGAA

NOVARTIS AG

NOVO NORDISK

PFIZER INC.

SANOFI

TAKEDA PHARMACEUTICAL CO. LTD.

CHAPTER 12 CONCLUSIONS: OUTLOOK FOR WOMEN'S HEALTH THERAPEUTICS

Major Developments to Influence Market
Therapeutic Developments
Demographic and Economic Trends
Income Growth in Emerging Markets
Future Outlook

CHAPTER 13 APPENDIX A: GLOSSARY OF TERMS

CHAPTER 14 APPENDIX B: INDUSTRY AND PROFESSIONAL ORGANIZATIONS

CHAPTER 15 APPENDIX C: ACRONYMS USED IN THIS REPORT

Acronyms Used in This Report

List Of Tables

LIST OF TABLES

Summary Table A: Global Market for Women's Health Therapeutics and Technologies, by Disease Area, Through 2026

Summary Table B: Global Market for Women's Health Therapeutics, by Region, Through 2026

Table 1: Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)

Table 2: Recent M&A Deals in the Global Market for Women's Health Therapeutics, 2019-2021

Table 3: Novel Breast Cancer Drug Approvals

Table 4: Selected New Breast Cancer Drugs in Late Stages of Clinical Development

Table 5: Pipeline Molecules, Endometriosis

Table 6: Pipeline Molecules, Uterine Fibroids

Table 7: Pipeline Molecules, All Other Indications

Table 8: Pipeline Molecules, Osteoporosis

Table 9: Elagolix Snapshot

Table 10: Vilaprisan Snapshot

Table 11: Evenity Snapshot

Table 12: Relugolix Snapshot

Table 13: Proellex Snapshot

Table 14: Esmya Snapshot

Table 15: TX-004HR Snapshot

Table 16: TX-001HR Snapshot

Table 17: Global Market for Women's Health Therapeutics and Technologies, by Disease Area, Through 2026

Table 18: FDA Approved Estrogen-only Medicines

Table 19: FDA Approved Progestin-Only Medicines

Table 20: FDA Approved Combination, Estrogen and Progestin Medicines

Table 21: FDA Approved Combination Estrogen and Hormone Medicines

Table 22: Vagifem (10mcg), Patent Expiration

Table 23: Global Market for Menopause Therapeutics, by Region, Through 2026

Table 24: Prolia/XGEVA (Denosumab) Patent Expiration

Table 25: Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026

Table 26: Global Market for Endometriosis Therapeutics, by Region, Through 2026

Table 27: Commonly Prescribed Generic Drugs for the Treatment of PCOS

Table 28: Global Market for PCOS Therapeutics, by Region, Through 2026
Table 29: TNM Classifications of Breast Cancers
Table 30: Global Breast Cancer Incidence, 2016-2021
Table 31: Global Breast Cancer Incidence and Mortality, by Region, 2018
Table 32: Types of Hormone Therapy for Breast Cancer
Table 33: Drugs Commonly Used to Treat Breast Cancer
Table 34: Global Market for Breast Cancer Therapeutics, by Region, Through 2026
Table 35: Global Market for Women's Health Therapeutics, by Region, Through 2026
Table 36: North American Market for Women's Health Therapeutics, by Country, Through 2026
Table 37: North American Market for Women's Health Therapeutics, by Disease Area Through 2026
Table 38: U.S. Market for Women's Health Therapeutics, by Disease Area Through 2026
Table 39: Canadian Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 40: Mexican Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 41: European Market for Women's Health Therapeutics, by Country, Through 2026
Table 42: European Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 43: U.K. Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 44: German Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 45: French Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 46: Spanish Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 47: Italian Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 48: Rest of the European Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 49: Asia-Pacific Market for Women's Health Therapeutics, by Disease Area, Through 2026
Table 50: RoW Market for Women's Health Therapeutics, by Sub-region Through 2026
Table 51: RoW Market for Women's Health Therapeutics, by Disease Area, Through 2026

Table 52: South American Market for Women's Health Therapeutics, by Disease Area, Through 2026

Table 53: Middle East and African Market for Women's Health Therapeutics, by Disease Area, Through 2026

Table 54: Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020

Table 55: Major Women's Health Therapeutics Pharmaceuticals by Company Revenue, 2020

Table 56: Global Market Shares of Women's Health Therapeutics, by Company Revenue, 2020

Table 57: Patent Review, 2021

Table 58: Novel Women's Health Therapeutic Drug Approvals, 2021

Table 59: Selected New Women's Health Therapeutic Drugs in Late Stages of Clinical Development

Table 60: Marketed Products, Postmenopausal Osteoporosis

Table 61: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020

Table 62: AbbVie Inc.: Net Revenue, 2017–2020

Table 63: AbbVie: Oncology Pharmaceutical Product Portfolio

Table 64: AbbVie Inc.: Marketed Products

Table 65: AbbVie Inc.: Key Developments, 2021

Table 66: Allergan plc: Marketed Products

Table 67: Allergan plc: Net Revenue, 2017-2019

Table 68: Amgen: Oncology Pharmaceutical Product Portfolio

Table 69: Amgen: Oncology Pharmaceutical Revenue, 2018-2020

Table 70: Amgen: Financials, 2014–2020

Table 71: AstraZeneca: Oncology Pharmaceutical Product Portfolio

Table 72: AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020

Table 73: Bayer AG: Marketed Products

Table 74: Bayer AG: Oncology Pharmaceutical Product Portfolio

Table 75: Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020

Table 76: Bayer AG: Net Revenue, 2018-2020

Table 77: Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio

Table 78: Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020

Table 79: Daiichi Sankyo Co. Ltd.: Marketed Products

Table 80: Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020

Table 81: Eli Lilly and Co.: Marketed Osteoporosis Products

Table 82: Eli Lilly and Co.: Net Revenue, 2018-2020

Table 83: Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio

Table 84: Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020

Table 85: Roche: Oncology Pharmaceutical Product Portfolio
Table 86: Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 87: Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
Table 88: Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 89: Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
Table 90: Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 91: Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
Table 92: Merck & Co. Inc.: Marketed Products
Table 93: Merck & Co. Inc.: Net Revenue, 2017–2019
Table 94: Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
Table 95: Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 96: Merck KGaA Marketed Products
Table 97: Novartis: Oncology Pharmaceutical Product Portfolio
Table 98: Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 99: Novo Nordisk: Marketed Products
Table 100: Novo Nordisk: Net Revenue, 2017–2019
Table 101: Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
Table 102: Pfizer Inc.: Women's Health-Marketed Products, by Indication
Table 103: Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 104: Pfizer Inc. Net Revenue, 2017–2019
Table 105: Sanofi: Oncology Pharmaceutical Product Portfolio
Table 106: Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Table 107: Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
Table 108: Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
Table 109: New Cancer Cases in the U.S., by Age Group, 2018
Table 110: Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
Table 111: Glossary of Terms Used in Women's Health Therapeutics
Table 112: Acronyms Used in Women's Health Therapeutics

List Of Figures

LIST OF FIGURES

Summary Figure A: Global Market for Women's Health Therapeutics, by Disease Area, 2020-2026

Summary Figure B: Global Market for Women's Health Therapeutics, by Region, 2020-2026

Figure 1: Distribution of Global Elderly Population, by Age Group and Sex, 2020

Figure 2: Distribution of Global Elderly Population, by Age Group and Sex, 2050

Figure 3: Funding for Research in Women's Health, by Disease Condition/Category, 2014-2016

Figure 4: Funding for Research in Women's Health, 2014-2016

Figure 5: Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014

Figure 6: Global Market for Women's Health Therapeutics, 2018–2026

Figure 7: Global Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 8: Global Market Shares of Women's Health Therapeutics, by Disease Area, 2026

Figure 9: Global Market for Menopause Therapeutics, 2020-2026

Figure 10: Global Market for Menopause Therapeutics, by Region, 2020-2026

Figure 11: Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016

Figure 12: Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026

Figure 13: Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020–2026

Figure 14: Global Market for Endometriosis Therapeutics, 2018–2026

Figure 15: Global Market for Endometriosis Therapeutics, by Region, 2020–2026

Figure 16: Global Market for PCOS Therapeutics, 2018–2026

Figure 17: Global Market for PCOS Therapeutics, by Region, 2018–2026

Figure 18: Global Market for Breast Cancer Therapeutics, 2018–2026

Figure 19: Global Market for Breast Cancer Therapeutics, by Region, 2020–2026

Figure 20: Global Market for Women's Health Therapeutics, by Region, 2020-2026

Figure 21: North American Market Shares of Women's Health Therapeutics, by Country, 2020

Figure 22: North American Market for Women's Health Therapeutics, 2018–2026

Figure 23: North American Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 24: North American Market for Women's Health Therapeutics, by Country, 2020–2026

Figure 25: U.S. Market for Women's Health Therapeutics, 2018–2026

Figure 26: Canadian Market for Women's Health Therapeutics, 2018–2026

Figure 27: Mexican Market for Women's Health Therapeutics, 2018–2026

Figure 28: European Market for Women's Health Therapeutics, by Country, 2020–2026

Figure 29: European Market Shares of Women's Health Therapeutics, by Country, 2020

Figure 30: European Market for Women's Health Therapeutics, 2018–2026

Figure 31: European Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 32: U.K. Market for Women's Health Therapeutics, 2018–2026

Figure 33: German Market for Women's Health Therapeutics, 2018–2026

Figure 34: French Market for Women's Health Therapeutics, 2018–2026

Figure 35: Spanish Market for Women's Health Therapeutics, 2018–2026

Figure 36: Italian Market for Women's Health Therapeutics, 2018–2026

Figure 37: Rest of the European Market for Women's Health Therapeutics, 2018–2026

Figure 38: Asia-Pacific Market for Women's Health Therapeutics, 2018–2026

Figure 39: Asia-Pacific Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 40: Asia-Pacific Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 41: Asia-Pacific Market for Women's Health Therapeutics, by Disease Area, 2020–2026

Figure 42: Chinese Market for Women's Health Therapeutics, 2018–2026

Figure 43: Japanese Market for Women's Health Therapeutics, 2018–2026

Figure 44: Indian Market for Women's Health Therapeutics, 2018–2026

Figure 45: South Korean Market for Women's Health Therapeutics, 2018–2026

Figure 46: Rest of Asia-Pacific Countries' Market for Women's Health Therapeutics, 2018–2026

Figure 47: RoW Market for Women's Health Therapeutics, by Sub-region, 2018–2026

Figure 48: RoW Market Shares of Women's Health Therapeutics, by Subregion, 2020

Figure 49: RoW Market for Women's Health Therapeutics, 2018–2026

Figure 50: RoW Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 51: South American Market for Women's Health Therapeutics, 2018–2026

Figure 52: South American Market Shares of Women's Health Therapeutics, by Disease Area, 2020

Figure 53: Middle East and African Market for Women's Health Therapeutics,

2018–2026

Figure 54: Global Market Shares of Women's Health Therapeutics, by Company, 2020

Figure 55: AbbVie: Hematologic Oncology Annual Revenue, 2018-2020

Figure 56: AbbVie Inc.: Revenue Share, by Country, 2020

Figure 57: Allergan plc: Revenue Share, by Business Segment, 2017

Figure 58: Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 59: AstraZeneca's Oncology Segment: Annual Revenue, 2018-2020

Figure 60: Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020

Figure 61: Bayer AG: Revenue Share, by Region, 2018

Figure 62: Bayer AG: Revenue Share, by Business Segment, 2018

Figure 63: Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020

Figure 64: Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014–2016

Figure 65: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018

Figure 66: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018

Figure 67: Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020

Figure 68: Roche: Oncology Annual Revenue, 2018-2020

Figure 69: Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020

Figure 70: Johnson & Johnson's Oncology Segment: Annual Revenue, 2018-2020

Figure 71: Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018

Figure 72: Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018

Figure 73: Merck & Co. Inc.: Revenue Share, by Business Segment, 2018

Figure 74: Merck & Co. Inc.: Revenue Share, by Region, 2018

Figure 75: Merck & Co.'s Oncology Pharmaceutical: Annual Revenue, 2018-2020

Figure 76: Novartis's Oncology Segment: Annual Revenue, 2018-2020

Figure 77: Novo Nordisk: Revenue Share, by Region, 2018

Figure 78: Novo Nordisk: Revenue Share, by Business Segment, 2018

Figure 79: Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020

Figure 80: Pfizer Inc.: Revenue Share, by Region, 2018

Figure 81: Pfizer Inc.: Revenue Share, by Business Segment, 2018

Figure 82: Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020

Figure 83: Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021

Figure 84: Rate of New Cancer Cases in the U.S., by Age Group, 2018

I would like to order

Product name: Therapeutics for Women's Health: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/T60FB243499EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T60FB243499EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970